<?xml version="1.0" encoding="UTF-8"?>
<p>The rapid spread of the COVID-19 pandemic has prompted the development of technological platforms adapted to this new pathogen and which could be employed to manufacture a safe and efficient vaccine. Currently, the World Health Organisationâ€™s draft landscape of COVID-19 vaccines has recorded over 100 SARS-CoV-2 candidate vaccines worldwide. Most of these candidate vaccines are undergoing preclinical evaluation, while 19 have already reached clinical evaluation. Of these, 14 vaccines are specifically based on the S protein (
 <xref rid="T3" ref-type="table">
  <bold>Table 3</bold>
 </xref>).
</p>
